Masanori Fujii

Dr. Masanori Fujii

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
MFMasanori Fujii
Masanori Fujii
Atopic dermatitis (AD) is a common chronic skin disease with multiple pathogenic factors including skin barrier dysfunction, immune abnormalities, and pruritus. This review summarizes components involved in these pathogenic factors. (1) Skin barrier dysfunction in AD could be due to the down-regulation of epidermal barrier components such as filaggrin, acylceramides, cornified envelope precursors, and claudin-1. (2) T helper type 2 (Th2) cell-derived cytokines, such as interleukin (IL)-4 and IL-13, and keratinocyte-derived cytokines, such as thymic stromal lymphopoietin (TSLP) and IL-33, contribute to Th2-mediated skin inflammation in AD. (3) IL-31, TSLP, IL-4, and IL-13 are able to directly activate primary sensory neurons to induce pruritus in AD, and increased susceptibility to itch (so-called alloknesis) is partly due to epidermal hyperinnervation. Importantly, the three key factors (skin barrier dysfunction, immune abnormalities, and pruritis) interact with each other, creating a positive feedback loop that leads to the induction and maintenance of AD. Therefore, a better understanding of not only each pathogenic factor but also their interactions is important to elucidate the complex pathophysiological mechanisms of AD, which will then lead to the development of new therapeutic strategies and drugs for the treatment of this common skin disease.

10 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
MFMasanori Fujii
Masanori Fujii
Ceramides play an essential role in forming a permeability barrier in the skin. Atopic dermatitis (AD) is a common chronic skin disease associated with skin barrier dysfunction and immunological abnormalities. In patients with AD, the amount and composition of ceramides in the stratum corneum are altered. This suggests that ceramide abnormalities are involved in the pathogenesis of AD. The mechanism underlying lipid abnormalities in AD has not yet been fully elucidated, but the involvement of Th2 and Th1 cytokines is implicated. Ceramide-dominant emollients have beneficial effects on skin barrier function; thus, they have been approved as an adjunctive barrier repair agent for AD. This review summarizes the current understanding of the mechanisms of ceramide abnormalities in AD. Furthermore, the potential therapeutic approaches for correcting ceramide abnormalities in AD are discussed.

1 December 2014 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
SMSayo Matsuba
Sayo Matsuba
SNSatomi Niwa
Satomi Niwa
KMKatsuhiko Muraki
Katsuhiko Muraki
SKSaki Kanatsuka
Saki Kanatsuka
YNYurika Nakazono
Yurika Nakazono
SOSusumu Ohya
Susumu Ohya
The Ca2+-activated Cl− channel transmembrane proteins with unknown function 16 A (TMEM16A; also known as anoctamin 1 or discovered on gastrointestinal stromal tumor 1) plays an important role in facilitating the cell growth and metastasis of TMEM16A-expressing cancer cells. Histone deacetylase (HDAC) inhibitors (HDACi) are useful agents for cancer therapy, but it remains unclear whether ion channels are epigenetically regulated by them. Using real-time polymerase chain reaction, Western blot analysis, and whole-cell patch-clamp assays, we found a significant decrease in TMEM16A expression and its functional activity was induced by the vorinostat, a pan-HDACi in TMEM16A-expressing human cancer cell lines, the prostatic cancer cell line PC-3, and the breast cancer cell line YMB-1. TMEM16A downregulation was not induced by the chemotherapy drug paclitaxel in either cell type. Pharmacologic blockade of HDAC3 by 1 μM T247 [N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1],[2],[3]triazol-4-yl]benzamide], a HDAC3-selective HDACi, elicited a large decrease in TMEM16A expression and functional activity in both cell types, and pharmacologic blockade of HDAC2 by AATB [4-(acetylamino)-N-[2-amino-5-(2-thienyl)phenyl]-benzamide; 300 nM] elicited partial inhibition of TMEM16A expression (∼40%) in both. Pharmacologic blockade of HDAC1 or HDAC6 did not elicit any significant change in TMEM16A expression, respectively. In addition, inhibition of HDAC3 induced by small interfering RNA elicited a large decrease in TMEM16A transcripts in both cell types. Taken together, in malignancies with a frequent gene amplification of TMEM16A, HDAC3 inhibition may exert suppressive effects on cancer cell viability via downregulation of TMEM16A.

10 May 2005 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
MFMasanori Fujii
Masanori Fujii
JTJunko Tomozawa
Junko Tomozawa
NMNobuaki Mizutani
Nobuaki Mizutani
TNTakeshi Nabe
Takeshi Nabe
KDKiichiro Danno
Kiichiro Danno
SKShigekatsu Kohno
Shigekatsu Kohno

26 March 2013 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
MFMasanori Fujii
Masanori Fujii
HNHiroyuki Nakashima
Hiroyuki Nakashima
JTJunko Tomozawa
Junko Tomozawa
YSYuki Shimazaki
Yuki Shimazaki
COChie Ohyanagi
Chie Ohyanagi
TNTakeshi Nabe
Takeshi Nabe

1 October 2015 in Allergology International
Verified
Journal Article
Open access
TSTomohiko Sekioka
Tomohiko Sekioka
MKMichiaki Kadode
Michiaki Kadode
MFMasanori Fujii
Masanori Fujii
KKKazuhito Kawabata
Kazuhito Kawabata
TATakashi Abe
Takashi Abe
TNTakeshi Nabe
Takeshi Nabe
The expression and functional role of CysLT2 receptors in asthma have not been clarified. In this study, we evaluated CysLT2 receptors expression, and effects of CysLT2-and CysLT1/2-receptor antagonists on antigen-induced bronchoconstriction using isolated lung tissues from both asthma and non-asthma subjects. CysLT1 and CysLT2 receptors expression in asthma and non-asthma lung tissue preparations was examined in immunohistochemistry experiments, and their functional roles in antigen-induced bronchoconstriction were assessed using ONO-6950, a dual CysLT1/2-receptor antagonist, montelukast, a CysLT1 receptor antagonist, and BayCysLT2RA, a CysLT2 receptor-specific antagonist. CysLT1 receptors were expressed on the bronchial smooth muscle and epithelium, and on alveolar leukocytes in 5 in 5 non-asthma subjects and 2 in 2 asthma subjects. On the other hand, although degrees of CysLT2 receptors expression were variable among the 5 non-asthma subjects, the expression in the asthma lung was detected on bronchial smooth muscle, epithelium and alveolar leukocytes in 2 in 2 asthma subjects. In the non-asthma specimens, antagonism of CysLT2 receptors did not affect antigen-induced bronchial contractions, even after pretreatment with the CysLT1-receptor specific antagonist, montelukast. However, in the bronchus isolated from one of the 2 asthma subjects, antagonism of CysLT2 receptors suppressed contractions, and dual antagonism of CysLT1 and CysLT2 receptors resulted in additive inhibitory effect on anaphylactic contractions. CysLT2 receptors were expressed in lung specimens isolated from asthma subjects. Activation of CysLT2 receptors may contribute to antigen-induced bronchoconstriction in certain asthma population.